Drugs that contain Lorlatinib
1. List of Lorbrena drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8680111 | PFIZER | Macrocyclic derivatives for the treatment of diseases |
Mar, 2033
(10 years from now) | |
| US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| US11299500 | PFIZER | Crystalline form of lorlatinib free base hydrate |
Oct, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 2, 2023 |
| Orphan Drug Exclusivity (ODE) | Mar 3, 2028 |
| New Indication (I) | Mar 3, 2024 |
NCE-1 date: November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic